(...) Two doses of the Oxford/AstraZeneca COVID-19 vaccine may be around 85% to 90% effective against symptomatic disease, Public Health England (PHE) said on Thursday, while cautioning that it did not yet have enough data to be conclusive.(...)In a weekly surveillance report, Public Health England said the estimated effectiveness of the AstraZeneca vaccine, invented at the University of Oxford, was 89% compared to unvaccinated people.
That compares to 90% estimated effectiveness against symptomatic disease for the Pfizer/BioNTech (PFE.N), vaccine.(...)"It is reassuring to see the data from both the Pfizer and Oxford AstraZeneca vaccines. They are essentially comparable in terms of effectiveness against symptomatic disease, which is very high after two doses," said Michael Head, Senior Research Fellow in Global Health at the University of Southampton.(...)
|